As shown in Fig. 2g–i, the decreased tumor volume and tumor weight were significant between DRAM1-Gefitinib and Gefitinib alone groups than that between DRAM1–PC9 and PC9 groups, suggesting that DRAM1 overexpression enhanced gefitinib sensitivity. The gene discussed is DRAM1; the disease is neoplasm.